Computational Approaches For Assessing Kinome Function And Deregulation by Murphy, Charles
 iii 
 
COMPUTATIONAL APPROACHES FOR ASSESSING KINOME FUNCTION 
AND DEREGULATION 
 
 
 
 
 
 
A Dissertation 
Presented to the Faculty of the Weill Cornell Graduate School 
of Medical Sciences 
in Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy 
 
 
 
 
 
by 
Charles Joseph Murphy 
August 2018 
  
 
 
 
 
 
 
 
 
 
 
 
© 2018 Charles Joseph Murphy 
ALL RIGHTS RESERVED 
 
 
 
 
 
 
 
 
 
 
  
COMPUTATIONAL APPROACHES FOR ASSESSING KINOME FUNCTION 
AND DEREGULATION 
Charles Joseph Murphy, PhD 
Cornell University 2018 
 
Protein kinases are a diverse family of about 500 proteins that all share the common 
ability to catalyze phosphorylation of the side chains of amino acids in proteins. 
Kinases play a vital role across diverse biological functions including proliferation, 
differentiation, cell migration, and cell-cycle control. Moreover, they are frequently 
altered across most cancers types and have been a focus for development of anti-
cancer drugs, which has led to the development of 38 approved kinase inhibitors as of 
2018. In this thesis, I developed two orthogonal computational approaches for 
investigating kinase function and deregulation. Starting with data from a large cohort 
of mouse triple negative breast cancer (TNBC) tumors, I use a combination of whole 
exome sequencing (WES) and RNA-seq to identify somatic alterations that drive 
individual tumors. I discovered that a large number of these alterations involve protein 
kinases and subsequent therapeutic targeting led to tumor regression. For my second 
approach, I utilized a large peptide library dataset from about 300 kinases. Which 
kinase phosphorylate which phosphorylation site is determined by both kinase-
intrinsic and contextual factors.  Peptide library approaches provide kinase-intrinsic 
amino acid specificity, which I used to predict novel kinase substrates and map out 
kinase phosphorylation networks. In summary, I developed methods using next-
  
generation sequencing and peptide library data to generate novel insights into protein 
kinase function and deregulation.
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CHAPTER 1   
INTRODUCTION 
 
 Kinases are crucial components for the normal functioning of cell biology 
(Manning et al., 2002; Weinberg, 2013). Kinases are a diverse set of proteins which 
all have a conserved catalytic domain of ~250 amino acids that catalyzes the 
phosphorylation reaction, the transfer of a phosphate from ATP to a serine (S), 
threonine (T), or a tyrosine (Y). There are at least 518 known kinases in the human 
genome and hundreds of thousands of known phosphorylation sites. The 
phosphorylation event is a vital signaling processing message that all cells use. Protein 
phosphorylation can enhance or impair protein interactions, activate or inactivate 
protein enzymatic activity, enhance or impair protein degradation or facilitate or 
impair re-localization to a different cellular compartment. Many of the known kinases 
have therefore been discovered to play vital roles in proliferation, differentiation, cell 
migration, and cell-cycle control.  
Kinases are also frequent causes of tissue dysfunction, notably cancer 
(Manning et al., 2002). In fact, the first gene to be discovered that could drive cancer 
was the tyrosine kinase, SRC (Weinberg, 2013). Since then, dozens of kinases have 
been implicated in driving cancer, leading to the development of 38 approved kinase 
inhibitors as of 2018 (Ferguson and Gray, 2018; Lemmon and Schlessinger, 2010). 
There are numerous mechanisms by which kinase function can be derailed. Mutant 
kinases can be deactivated or be made constitutively activated. The expression level of 
the kinase can be altered via genomic amplification or deletion as well as via 
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deregulation of gene regulatory networks. Gene fusions can pair the kinase with new 
protein function or regulation elements that affects the cellular localization or activity 
level of the kinase. Detecting and studying this plethora of ways by which kinases can 
be altered requires numerous types of technology.  
 
1.1 Kinase signaling networks underpin normal cell functioning 
 
The eukaryotic protein kinases domain contains two parts: an N-terminal lobe 
of b-sheets and C-terminal lobe of a-helices (Ubersax and Ferrell, 2007). Despite the 
highly conserved catalytic domain, there are functionally significant ways to group the 
kinases. One of the most important ways is based on whether they phosphorylate 
tyrosine or serine/threonine. Histidine, lysine and aspartate phosphorylation also occur 
in eukaryotic cells, though in most cases these modifications are intermediates in 
enzymatic reactions rather than transphosphorylation by a protein kinase. Only 20% of 
kinases are tyrosine kinases, differentiated from serine/threonine kinases by a set of 
highly conserved residues that provide room for the large, aromatic phosphoacceptor 
(tyrosine) (Taylor et al., 1995; Chen et al., 2014). Serine/threonine kinases contain 
conserved residues that allow for a small, aliphatic phosphoacceptor (serine or 
threonine). Moreover, some serine/threonine kinases show preference for either serine 
or threonine based on the presence of a single residue in the kinase activation segment 
termed “DFG+1” residue (Chen et al., 2014). Furthermore, the proportion of known 
phospho-tyrosines (pY), phospho-serines (pS), and phospho-threonines (pT) that have 
been identified reflects the relative number of protein kinases with selectivity for each 
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of the three amino acids. Generally, pS makes up ~86%, pT makes up ~12%, and pY 
makes up ~2% of known phosphorylation sites (Newman et al., 2014).  The somewhat 
disproportional abundance of pS can be accounted for by the fact that some Ser 
kinases have dozens or even hundreds of substrates. 
Kinases can be further grouped into families based on evolutionary and 
functional relationships. A phylogenetic tree constructed based on the kinase domain 
demonstrates that kinases can be broken down into families, such as the SRC, FGFR, 
and Eph families (Figure 1-1). The FGFR family for example consists of four 
members: FGFR1, FGFR2, FGFR3, and FGFR4. These four tyrosine kinases are 
structurally similar and are critical in embryogenesis and organogenesis, as well as 
mediating metabolic functions, tissue repair, and regeneration in adult tissues (Ornitz 
et al.).  Although kinases from the same family often share similar function, outside 
the conserved kinase domain are a diverse set of other regulatory and catalytic 
domains that further specify kinase function. These enable kinase-specific tissue- and 
cellular-specific expression patterns and placement within protein interaction 
networks. One example is the distinction between receptor and non-receptor tyrosine 
kinases. Receptor tyrosine kinase (RTKs) all contain an extracellular ligand domain, a 
single transmembrane helix, and a cytoplasmic region containing the kinase domain 
and other regulatory domains (Lemmon and Schlessinger, 2010). There are 58 human 
RTKs and these are an important class of signaling kinases for cellular proliferation, 
differentiation, metabolism, and more. Importantly, RTKs are frequently involved in a 
variety of human diseases. 
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Figure 1-1: Family tree of the human kinome.  
Reprinted with permission from Trends in Biochemical Sciences (Taylor and Kornev, 
2011). Shows the family groupings of the protein kinases. 
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Phosphorylation is responsible for most of cell signal transduction, which 
effects such fundamental processes as cell proliferation, movement, apoptosis, and 
differentiation. With over 500 kinases and hundreds of thousands of known 
phosphorylation sites, which kinase phosphorylates which serine, threonine, and 
tyrosine is determined by both kinase-intrinsic and contextual factors (Figure 1-2) 
(Hornbeck et al., 2004; Dinkel et al., 2011). Although all kinases have the conserved 
kinase catalytic cleft, the surface charge and hydrophobicity around the binding pocket 
where the substrate binds can vary. This leads to each kinase preferring certain types 
of amino acids C-terminal and N-terminal from the central serine, threonine, or 
tyrosine (Ubersax and Ferrell, 2007). Additional contextual factors such as cellular 
localization, protein-protein interaction networks, tissue expression, intrinsic 
instability of the substrate protein, and others factors determine whether a site can be 
phosphorylated and by which kinase. 
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Figure 1-2: Determinants of kinase phosphorylation. 
The top four squares show different contextual factors that influence which substrates 
a kinase can phosphorylate. The bottom of the figure outlines the phosphorylation 
reaction. 
 
1.2 Kinases are frequent drivers of cancer 
 
 Recent large-scale cancer studies have revealed the extent of involvement of 
kinases in human cancer. Lawrence et al. identified 260 recurrently point mutated 
genes across 21 tumor types, and 27 (10.3%) of them are in protein kinases (Figure 1-
3) (Lawrence et al., 2014). This is significant considering that only ~2% of human 
genes are protein kinases. Yoshihara et al. examined gene fusions across 4366 tumors 
from 13 tumor types and found that 324 (7.4%) of samples contained in-frame fusions 
involving protein kinases (Yoshihara et al., 2015). Furthermore, Stransky et al. 
examined fusion kinases that occur in ≥ 2 samples across 6,893 tumors and 20 solid 
tumor types (Stransky et al., 2014). They found that about 3% of samples contain at 
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least one of the recurrent fusions and conclude there is significant therapeutic potential 
for targeting them. Beroukhim et al. analyzed recurrent somatic copy number 
alterations across 3,131 samples from 31 histological cancer types and found an 
enrichment of kinases in amplified regions (Beroukhim et al., 2010). These are other 
cancer-specific studies repeatedly demonstrate the pervasive involvement of protein 
kinases in driving cancer. 
 
Figure 1-3: Driver kinases identified from cancer genomic studies. 
Reprinted with permission from Nature Reviews (Fleuren et al., 2016). (A) Shows the 
kinase family tree annotated with somatic alterations common to particular kinases. 
(B) Shows the mutation frequency of different kinases by cancer type. 
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Somatic alterations frequently act indirectly on kinases by being located 
elsewhere within the kinase signaling pathway (Campbell et al., 2016; Brognard and 
Hunter, 2011). A recent review not only confirmed that kinases are enriched among 
the compiled list of 1,100 cancer driver genes, but that 12% of them were substrates of 
kinases (Fleuren et al., 2016). The PI3K-mTOR and MAPK pathways are some of the 
most frequently altered pathways in cancer. The main effector protein kinases of the 
PI3K pathway are the AKT1/2/3 family.  Numerous somatic mutations in genes 
upstream of AKT have been documented including loss of function PTEN deletions, 
gain of function mutations in PI3K (a lipid kinase), and gain of function mutations or 
amplifications in AKT1, AKT2 or AKT3. Furthermore, as discussed in Chapter 2, a 
survey of the genomic landscape of a mouse model of TNBC revealed potential 
oncogenic alterations in ~50% of the tumors, most of which resulted in the ability to 
activate protein kinases in the MAPK/PI3K pathways, even though not all genetic 
aberrations directly affected a known protein kinase (H. Liu et al., 2017).  
 
1.3 The mechanisms of somatic alterations for changing kinase activity 
 
The mechanisms by which kinase function can be altered by a somatic 
alteration are varied. The somatic alterations can either directly affect kinase activity 
by altering its genomic sequence, expression level, turnover rate, or its protein 
substrates. The RTK class of kinases is most often the target of somatic alterations 
(Fleuren et al., 2016; Lemmon and Schlessinger, 2010). The RTKs generally work via 
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ligand-induced dimerization and subsequent auto-transphosphorylation of the 
activation loop of the protein kinase domain. There are four general mechanisms by 
which alterations can lead to aberrant RTK activity. First, mutations that lead to 
constitutive activation of the kinase such as KIT mutations found in a variety of 
cancers that relieve the auto-regulatory inhibition of KIT’s tyrosine kinase domain. 
Second, RTK overexpression either through gene regulation or amplification can lead 
to ligand-independent dimerization and activation of the RTK as was observed for 
MET amplification (H. Liu et al., 2017). Third, the kinase domain of the RTK can be 
fused with another gene leading to its overexpression or constitutive activation. 
FGFR2-CCDC6 and FGFR2-DNM3 fusions found in breast cancer were shown to be 
constitutively active due to stable formation of homo-multimerization complexes 
mediated by the CCDC6 and DNM3 C-terminal fusion partners (H. Liu et al., 2017). 
Forth, RTKs can become overly active via autocrine activation. 
 Mutation of the phosphorylation site or its flanking regions is another 
important mechanism. Reimand et al. analyzed somatic mutations from 3,185 tumors 
across 12 cancer types to assess their impact on known phosphorylation sites. They 
found that 90% of tumors harbored mutations at or near phosphorylation sites, and 
predicted that 29% of them either abolish the phosphorylation site or modify it in 
some way that rewires kinase signaling (Reimand et al., 2013). Several tools have 
been released that examine the impact of mutations for rewiring phosphorylation 
signaling networks. Pau et al. created ReKINect that predicts three classes of 
mutations that affect phosphorylation networks (Creixell, Schoof, et al., 2015). First, 
mutations that directly affect the kinase by making it constitutively “on” or “off”. 
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Second, mutations in upstream or downstream components of a kinase’s network. 
Upstream mutations affect the linear motif surrounding a phosphorylation site, which 
can lead to a new kinase being able to phosphorylate it. Downstream mutations occur 
on the kinase and affect its determinates of specificity, which are the key amino acids 
in the kinase domain that determine its motif preference. Third, mutations that can 
create or destroy phosphorylation sites. Another tool that examines mutational effects 
on phosphorylation sites is MIMP (Wagih et al., 2015). In contrast to ReKINect, 
MIMP predicts just whether a given mutation creates or destroys a phosphorylation 
site. MIMP was tested on 236,367 mutations from 3,185 tumors across 12 tumor types 
and revealed that 34,996 of them were within 7 residues of known phosphorylation 
sites and 7,092 were predicted to either create a site, destroy a site, or switch the 
phosphorylating kinase. 
 
1.4 In this dissertation 
 
In this dissertation I present analyses from two orthogonal technologies for 
studying kinase function and deregulation. In chapter 2 I describe the use of RNA-seq 
and WES to identify mutations, gene fusions, and copy number alterations in a mouse 
model of TNBC. Through collaboration, I was able to then show that most of the 
oncogenic alterations involved protein kinases and show that drugs that target the 
activated protein kinase pathway were effective in treating the cancers.  In Chapter 3 I 
present a strategy to predict proteins substrates of protein kinases utilizing data 
generated from the oriented peptide libraries to determine the peptide substrate 
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specificity of a wide range of protein kinases. I demonstrate how next-generation 
sequencing and peptide libraries are two orthogonal technologies that provide depth of 
understanding into the function and deregulation of protein kinases in human disease. 
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CHAPTER 2  
ONCOGENIC KINASE DRIVERS IN MOUSE TRIPLE NEGATIVE BREAST 
CANCER 
 
Breast cancer is one of the leading causes of cancer-related deaths for females 
in the United States. TNBC is a deadly form of breast cancer defined by the lack of 
expression of estrogen receptor (ER), progesterone receptor (PR), and HER2 (Foulkes 
et al., 2010). TNBC is a heterogeneous disease with few recurrent alterations except 
TP53 alterations (~80%), the PI3K pathway (PIK3CA, PTEN, and INPP4B) 
alterations, and BRCA1 germline alterations (Shah et al., 2012; Davies et al., 2016). 
Furthermore, transcriptional profiling of TNBC revealed a number of subtypes each 
with their own treatment distinctions (Masuda et al., 2013; Lehmann et al., 2011). 
TNBC is therefore a difficult disease to treat since no single therapy can be designed 
to target a majority of patients. Instead, treatment must be tailored to individual 
patients according to their tumor makeup (H. Liu et al., 2017). 
Kinases are frequent alterations in breast cancer and TNBC. The Cancer 
Genome Analysis (TCGA) dataset for mutated genes in 510 breast tumors revealed 3 
(8.6%) of the 35 significantly mutated genes were protein kinases (Koboldt, Fulton, et 
al., 2012). They also confirmed the presence of recurrent copy number alterations in 
the EGFR, ERBB2, STK11, and MAP2K4 protein kinases. Yoshihara et al. found that 
105 (8.6%) out of 1,228 breast tumors harbored in-frame protein kinase fusions. 
Although breast cancer is a very heterogenous disease with many somatic alterations, 
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with non-protein kinase such TP53, PTEN, and PIK3CA being among the most 
frequent, many of these alterations occur within protein kinase signaling networks.  
In order to study aberrant kinases in TNBC, I used data from a genetically 
engineered mouse (GEM) model in collaboration with Hui Liu, who performed all the 
mouse work, molecular assays, and treatment. GEM models are useful for modeling 
human cancers and exploring treatment options (Frese and Tuveson, 2007). GEM 
models are one of the more sophisticated animal models for human cancer by allowing 
mice to be genetically engineered with mutations that predispose them to specific 
types of cancer. This allows the mouse cancer to be studied throughout the course of 
its evolution as well as to have various experimental treatments applied to it. 
Herein, we utilized a TNBC GEM model in order to characterize the genomic 
and transcriptomic landscape of mouse and apply precision medicine treatment to cure 
individual mouse tumors. Our model is the Trp53 flox/flox with our without Brca1flox/flox, 
which have been shown to be strongly predisposed to develop breast cancer with 
basal-like characteristics (X. Liu et al., 2007)(Figure 2-1).  To achieve this, we 
performed next-generation sequencing on 72 unique mouse primary tumors for our 
study. In total, we collected we 67 RNA-seq samples from primary tumors, three 
RNA-seq samples from normal mammary, 63 WES samples from primary tumors, 29 
WES samples from paired tail tissue, and 3 WES samples from normal liver tissue. 
We demonstrated that the TNBC GEM model recapitulates many characteristics of 
human TNBC, including somatic alteration heterogeneity, low mutation rate, higher 
gene fusion rate, and similar transcriptional profiles. Finally, we successfully used the 
mouse model as a precision medicine model for human TNBC by identifying tumor 
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drivers and targetable alterations. Moreover, we found that many of the oncogenic 
alterations involved protein kinases. Thus, lending credence to using next-generation 
sequencing to discover somatically altered kinases. 
 
 
Figure 2-1: Generation of mouse TNBC tumors. 
Our breeding strategy to generate the K14cre; p53 flox/flox; Brca1WT/WT and K14cre; p53 
flox/flox; Brca1flox/flox mice. 
 
2.1 Modeling human TNBC 
 
Establishing that our mouse model accurately reflects human TNBC is important 
prior to drawing conclusions that can affect clinical decision making for human 
patients. Our mouse model is a GEM model, which means the tumors are endogenous 
to the mouse, in contrast to the commonly used xenograft, which graft human tumors 
into an immunodeficient mouse (Frese and Tuveson, 2007). There are important 
limitations to consider for all mouse models, but one important limitation of GEM 
models is how well they reproduce the kinetics of tumor evolution. Human tumors 
develop over the course of years or decades, whereas tumors in GEM models usually 
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develop rapidly with the simultaneous perturbation of one or more driver genes. This 
can therefore lead one to expect fewer total number of somatic alterations that 
accumulate. Moreover, mice have longer telomeres compare to humans and will take 
longer to shorten enough to cause genomic instability, which is an important role in 
oncogenesis. Hence, assessing the phenotypic and genetic similarity to the human 
disease counterpart is vital. 
Human TNBC is defined as the lack of expression of ER, PR, and HER2 (Foulkes 
et al., 2010). Thus, we stained a select representative set of the mouse tumors for these 
receptors (Figure 2-2), demonstrating the tumors are negative for all three. Moreover, 
previous research has demonstrated that ER, PR, and HER2 status can be determined 
using RNA-seq. We applied a logistic classifier to each tumor to determine ER, PR, 
and HER2 status, revealing that the majority of tumors are negative for all three 
(Figure 2-3). 
 
 
Figure 2-2: Representative staining for ER, PR, and HER2. 
H&E and IHC staining of ER, PR, and HER2 for tumors. 
 
I next used two published classifiers to determine which breast cancer intrinsic 
subtypes each tumor falls into. One of the first transcriptional subtype classifiers for 
breast cancer, PAM50, divided all breast cancers into one of five types: Basal-like, 
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Luminal A, Luminal B, HER2-enriched, and Normal-like (Parker et al., 2009). These 
subtypes are associated with various clinical parameters including chemotherapy 
efficacy and pathological complete response. Prior to classifying the mouse tumors I 
first converted mouse gene symbols to human gene symbols using the vertebrate 
homology list provided by Mouse Genome Informatics. I then re-estimated the 
PAM50 centroids using RNA-seq expression profiles from TCGA BRCA data and 
PAM50 assignments in the original TCGA BRCA publication as ground truth for 
cross validation (Koboldt, Fulton, et al., 2012; Parker et al., 2009). After computing 
the within-sample rank normalization on the RPKM measurements, I achieved 82% 
classification accuracy after 10-fold cross-validation on the human BRCA TCGA data. 
I then classified the mouse tumors after rank normalizing the mouse FPKM values. I 
found that the majority of mouse tumors classify as basal-like (Figure 2-3). 
The second classifier I used is the Absolute Intrinsic Molecular Subtype 
(AIMS) classifier. AIMS uses a large set of rules that examine the relative expression 
of genes within the sample combined into a Naïve Bayes framework. Prior to 
classification, I converted mouse gene symbols to human Entrez gene IDs using 
BioMart and the vertebrate homology list provided by Mouse Genome Informatics 
(Kinsella et al., 2011; Blake et al., 2017; Paquet and Hallett, 2014). Again, I found 
that the majority of mouse tumors classified as basal-like (Figure 2-3). 
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Figure 2-3: Classification of mouse transcriptomes into TNBC. 
(A) Transcriptional classification of mouse tumors using the AIMS classifier into one 
of five intrinsic breast cancer subtypes. (B) Transcriptional classification of mouse 
tumors using the PAM50 classifier into one of five intrinsic breast cancer subtypes. 
 
 
 I further confirmed that our mouse tumors are transcriptionally similar to 
TNBC by taking an unsupervised approach by clustering (spearman correlation 
distance, average linkage) on the mouse tumors with breast cancer RNA-seq 
expression profiles from TCGA on the 137 shared genes between mouse and human 
that were part of the AIMS signature (Figure 2-4). RNA-seq expression profiles for 
TCGA breast cancer (BRCA) samples were downloaded from Broad GDAC Firehose 
(http://gdac.broadinstitute.org/) data version 2016_01_28. I found that the mouse 
tumors clustered with human TNBC tumors. 
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Figure 2-4: Unsupervised clustering of mouse TNBC with human TNBC. 
Mouse TNBC tumors (light and dark green) clustered with human TNBC (red). Genes 
used for clustering are the genes used in the AIMS classifier. 
 
 In summary, I found that our mouse tumors are similar to TNBC. Staining 
from a representative set of tumors indicate that the tumors are negative for PR, ER, 
and HER2. Likewise, logistic regression on the RNA-seq indicate most tumors are 
negative for PR, ER, and HER2. I also classified each mouse tumor according to the 
intrinsic breast cancer subtypes using two classifiers, finding that the majority of 
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tumors are basal-like. This finding is significant because 70-80% of human TNBC 
tumors are basal-like. Finally, I took an unsupervised approach that revealed that our 
mouse tumors clustered with human TNBC. Hence, I concluded that our mouse 
tumors model human TNBC. 
 
2.2 Characterization of the mouse TNBC transcriptome and genome 
 
The transcriptome and genome of mouse breast cancer has been previously 
characterized to a smaller extent using high-throughput technologies. Liu et al. first 
established the K14cre;p53flox/flox;BRCA1flox/flox mouse model used in our experiments. 
Using array CGH for CNAs and microarray for gene expression profiling, they found 
high rates of genomic instability and similar transcriptional profiles to human breast 
cancer (X. Liu et al., 2007). Pfefferle et al. used a combination of microarray, whole-
genome sequencing, and whole-exome sequencing to profile the transcriptome and 
genome of a number of BALB/c; Trp53-null mice (Pfefferle et al., 2016). In addition 
to finding an unstable genome and being transcriptionally similar to certain human 
breast cancer subtypes, they identified somatic alterations that were also found in 
human breast cancer. These include amplifications and deletions such as Met, Cul4a, 
Lamp1, Pnpla6, and Tubgcp3 that can potentially be targeted by drugs. Ben-David et 
al. used microarray expression profiles to characterize the CNA landscape of a number 
of breast cancer mouse models, including Brca1-/- and a p53-/- models (Ben-David et 
al., 2016). They found the various mouse models had significant differences in CNAs 
profiles, and some recurrent alterations were also found in human cancer. Thus, the 
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main findings for these studies include genomic instability with high copy number 
rates, transcriptional profiles similar to human breast tumors, few recurrent alterations, 
and some overlap with known alterations that occur in human breast cancer with 
potential as therapeutic targets. 
In this thesis, I characterized the most comprehensive set of the mouse breast 
cancer genomes and transcriptomes to date using combined RNA-seq and whole-
exome sequencing on the primary tumors. I identified a heterogeneous number of 
somatic gene fusions, mutations, and CNAs, many of which involved protein kinases. 
 
2.2.1 Gene Fusions 
 
Gene fusions result from the inter- or intra-chromosomal fusion of DNA 
strands, that can impair gene function, rearrange gene regulatory elements, or create 
novel gene products by fusing the coding sequences of two genes. Gene fusions are a 
major source of driver events across a variety of human cancers, especially breast 
cancer (Yoshihara et al., 2015; Stephens et al., 2016; Shaver et al., 2016). Among all 
types of breast cancer, TNBC has one of the highest rates of gene fusion events 
(Figure 2-5) (Yoshihara et al., 2015). Thus, I sought to identify gene fusions present in 
our mouse model of TNBC, reasoning they are a likely abundant source of tumor 
drivers. 
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Figure 2-5: Pan-cancer gene fusion rate. 
Number of gene fusions per tumor across a variety of human cancers (data from 
TCGA). Human TNBC has the highest rate of gene fusions. 
 
I used FusionCatcher (v0.99.5a) with mouse reference genome GRCm38 to 
identify gene fusions in our mouse TNBC tumors (Nicorici et al., 2014). I removed 
likely false positive gene fusions by removing those found in any of the three normal 
mammary controls, were marked as read-throughs, or occurred with the same 
breakpoint and gene partners in three or more independent primary tumors. The 
tumors harbored a very heterogeneous array and number of gene fusions (average of 4 
and range of 0 to 16 per tumor), with few being present in more than one tumor 
(Figure 2-6). 
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Figure 2-6: Gene fusions in mouse primary tumors. 
Rows are unique fusions and columns are unique samples. Top graph shows the 
number of gene fusions per tumor and the bottom shows the BRCA1 genotype. 
 
I found numerous in-frame gene fusions that involved protein kinases with 
intact kinase domains (Figure 2-7). The kinases involved include Fgfr2, Met, Raf1, 
and Braf. Surprisingly, I found several fusions involving Fgfr2 as the 5’ partner but 
with different 3’ gene partners. In-frame fusions involving FGFR2, BRAF, RAF, and 
MET have all been found previously in human breast cancer, but with different gene 
partners compared. Several FGFR2 fusions have been found in breast cancer, which 
were demonstrated to be sensitive to the FGFR inhibitors PD173074 and pazopanib 
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(Wu et al., 2013). One fusion involving BRAF and RAF1 each have also been found in 
breast cancer (Matissek et al., 2018). The RAF1 fusion was demonstrated to activate 
downstream signaling and induce cell growth, polarity, and survival on mammary 
epithelia. The BRAF fusion has also been previously found in several lung cancer 
patients and shown to induce MAPK signaling (Jang et al., 2015). Finally, data from 
TCGA breast cancer data revealed a patient with a MET fusion and another with a 
FGFR2 fusion (Yoshihara et al., 2015). 
 
 
Figure 2-7: Sample of in-frame kinase fusions. 
Displayed are the protein domain structures of the selected kinase fusions. The gene 
symbols of the two involved genes are listed at the top. The vertical black line 
indicates the fusion point. Domain names are listed below the rectangular box. 
 
 
 
 
Tyrosine kinase 
domain
Other domains
Fgfr2-Tns1
Fgfr2-Dnm3
Dhx9-Raf1
Rpl32-Raf1
Fgfr2-Zmynd8
Dlg1-Braf
Met-Calu
Met-Itsn1
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2.2.2 Copy number alterations 
 
CNAs are regions of a chromosome or whole chromosomes that gain or lose 
one or more copies, and are very common in cancer (Zack et al., 2013; Beroukhim et 
al., 2010). Identifying oncogenic CNAs is usually done by looking for genes that are 
focally and recurrently amplified or deleted and by looking for CNAs that overlap 
known cancer genes. A recent study examined 4,934 tumor samples from 11 cancer 
types and found 140 regions that were recurrently and focally subject to CNAs, 102 
occur in known cancer genes and 50 in significantly mutated genes. Human breast 
cancer, especially TNBC, haver higher than average CNA rates and so have very 
heterogenous CNA landscapes (Figure 2-8).  
 
 
Figure 2-8: Pan-cancer CNA rates. 
(A) Genomic instability index per tumor across cancer types. (B) Number of 
breakpoints per tumor across cancer types. 
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The CNA landscape of our mouse TNBC model using a customized pipeline. 
Before calling CNAs with CNVkit (v0.8.1) I filtered out reads with mapping quality 
less than 30 and read pairs that map to different chromosomes using samtools 
(Talevich et al., 2016). I used separate strategies to call CNAs in tumors sequenced 
with the SureSelect and NimbleGen kits. 
CNAs of tumors sequenced with the SureSelect kit were called using a panel of 
three livers as controls. However, the built-in GC-content bias correction within 
CNVkit was not sufficient. I observed increased variance in log2 coverage ratios 
(tumor over liver) in capture regions with lower GC content (data not shown); 
therefore, I developed an algorithm to correct the variance. Let 𝐿"#  be the log2 
coverage ratio in capture region k and sample i. Let 𝐺𝐶& denote the set of all capture 
regions 𝑘 where GC content is j (in intervals of 1%). Then I compute 𝑚"& as the 
median absolute deviation (MAD) of all 𝐿"# , where 𝑘 ∈ 𝐺𝐶&. I then computed the 
value M, which is the median of all the 𝑚"& values. I then calculated, 𝐿𝑐"#, the 
corrected log2 coverage ratio with the following equation: 
 
𝐿𝑐"# = 𝑀𝑚"& 𝐿"#, 𝑤ℎ𝑒𝑟𝑒	𝑘 ∈ 𝐺𝐶& 
 
I demonstrated that this correction significantly improves segmentation results as 
determined by comparison to an independent algorithm, CopywriteR (v2.4), which can 
call CNAs without the need for a control sample (Kuilman et al., 2015). CopywriteR 
was not used as the primary CNA analysis because its results are noisier than CNVkit 
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results but provides an important benchmark by which I demonstrated the validity of 
our CNA calling strategy. Using the same set of filtered reads as used for CNVkit I ran 
CopywriteR with window size set to 40kbp and the SD parameter set to 1 for the 
segmentation step. I compared CNVkit and CopywriteR results by computing the 
weighted Euclidean distance between final segmentation results, where the weight is 
the length in base pairs of each segment. However, before I computed the Euclidean 
distance, I standardized the segmentation values by subtracting the mean and dividing 
by the standard deviation computed from the capture region log2 ratios. The variance 
correction significant decreased the weighted Euclidean distance between CNVkit and 
CopywriteR results (p-value < 0.01, paired Student t-test). 
Tumors sequenced using the NimbleGen kit had no suitable reference due to 
poor quality tail DNA and subsequent low-quality sequencing results; and the livers 
could not be used as a control either due to being sequenced with a different capture 
kit. Instead, all tumors sequenced with the NimbleGen kit were used as a combined 
reference using CNVkit. After CNVkit corrected the combined reference for GC and 
mappability biases, I applied an additional correction that mitigated any bias 
introduced by any recurrent regions of amplification or deletion in the tumors using 
local regression (LOWESS). I expected there to be even coverage across the genome, 
which I confirmed by looking at the median-centered log2 coverage in the liver 
samples plotted along the genome. First, I sorted the probes by genomic position, and 
for each chromosome separately, applied our LOWESS correction using the loess R 
function with span=0.1 and where data was weighted by their normal density from the 
dnorm R function where mean was set to median and sd set to the standard deviation 
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across all log2 coverage values. Weighting the data was necessary to reduce the 
impact of outlier and low-coverage regions. 
I used a previously published approach to identify thresholds for copy number 
changes in each sample (Geyer et al., 2017). Briefly, I sorted the log2 ratios of each 
capture region and calculated the median and standard deviation from the 50% central 
exon capture regions. I defined copy number segments with log2 ratio -2.5 or -7 
standard deviations below the median as copy number losses and deep deletions, 
respectively. Copy number segments with log2 ratio +2 or +6 standard deviations 
above the median were copy number gains and amplifications, respectively. Finally, 
for the purpose of visualization and comparison across samples, I rescaled the log2 
copy number ratios for each sample by dividing the negative log2 ratios by the deep 
deletion threshold and positive copy number ratios by the amplification ratio. 
I found that tumors from our mouse model were moderately genomically 
unstable and had complex CNA landscapes (Figure 2-9). A heterogenous CNA 
landscape is in accordance with what has been observed in human TNBC. 
Furthermore, the CNA rate is higher in the Brca1 deletion group (Figure 2-10), which 
was expected and has been previously been observed given the role Brca1 plays in 
DNA repair (Holstege et al., 2010). 
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Figure 2-9: Copy-number alteration landscape of mouse TNBC. 
Copy gains are in red and copy losses are in blue. X-axis shows chromosome number 
and y-axis shows individual samples annotated with Brca1 genotype. 
 
Figure 2-10: CNA rate comparison between Brca1 genotype. 
Number of CNA breakpoints per tumor is significantly different by Brca1 genotype. 
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I found several known oncogenic genes that were subject to focal CNAs, 
including some that were recurrent. Met, Myc, and Yap1 were focally amplified in the 
numerous samples (Figure 2-11). For most of the amplified samples, the expression of 
the amplified gene was also higher. Furthermore, I discovered several other known 
oncogenic genes that were amplified or deleted in single samples, including Pten 
deletion, Fgfr2 amplification, and Egfr amplification (Figure 2-12). MET (Graveel et 
al., 2009; Ponzo et al., 2009), EGFR (Brandt et al., 2000; Marozkina et al., 2008; 
Masuda et al., 2012), YAP1 (S.-S. Chang et al., 2017; Yu et al., 2015; Zanconato et 
al., 2016), FGFR2 (Easton et al., 2007; Katoh, 2016), and PTEN (J. C. Liu et al., 
2014; Wang et al., 2016) have all been previously shown to drive TNBC. In addition 
to their putative driver role, Met, Fgfr2, and Egfr encode protein kinases. 
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Figure 2-11: Recurrent focal amplifications. 
Met (top row), Yap1 (middle row), and Myc (bottom row) were focally and recurrently 
amplified in the mouse tumors. The left-hand side figures show the genomic position 
of the amplification for each sample (one per row). The vertical yellow line is the 
approximate location of the gene. The right-hand side figures plot the expression of 
each gene against the log2 copy number of the gene. Samples in red are those that 
were amplified based on the CNA data. 
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Figure 2-12: Single focal amplifications. 
Fgfr2 (top row), Egfr (middle row), and Pten (bottom row) were focally amplified in 
single tumors. The left-hand side figures show the genomic position of the 
amplification for each sample (one per row). The vertical yellow line is the 
approximate location of the gene. The right-hand side figures plot the expression of 
each gene against the log2 copy number of the gene. Samples in red are those that 
were amplified based on the CNA data. 
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2.2.3 Mutations 
 
Human breast cancer is known to have a relatively low mutation rate compare 
to other cancers, with an average rate of 90 mutations per tumor in the coding exons 
(Figure 2-13).  Human TNBC is a little higher at 127 mutations per tumor. 
Furthermore, there are very few recurrent mutations in TNBC. One study found on 
104 TNBC patients found TP53 to be the most frequent (62%), followed by PIK3CA 
(10.2%), USH2A (9.2%), MYO3A (9.2%), and PTEN and RB1 at 7.7% (Shah et al., 
2012). 
 
 
Figure 2-13: Pan-cancer mutation rate. 
Plotted is the average number of mutations in the coding exons per tumor for various 
cancer types in TCGA. 
 
I called mutations using Varscan2 on each tumor-normal pair (Koboldt, Zhang, 
et al., 2012). If no normal tail sample was available for a tumor, I combined the three 
normal liver samples as a normal control for somatic mutation calling. For calling 
mutations from RNA-seq I applied the additional pre-processing step of removing 
PCR duplicate reads. Varscan2 default parameters were used except: minimum read 
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mapping quality of 15, minimum base quality of 15, at least four supporting reads, 
minimum sequencing depth of 12, minimum variant frequency of 5%, and p-value ≤ 
0.01. Since not all sequenced tumors had matched normal controls, I applied a 
stringent filtering criterion to reduce potential false positive germline mutations. I 
removed mutations that had 4 or more variant supporting reads in any of the control 
samples (with minimum base and mapping qualities of 10) or for which there were 
fewer than 10 normal control samples with coverage less than 12. I then removed any 
mutations that were outside the exon capture regions, were found in any of the 
immunoglobulin, histocompatibility, or killer cell lectin like receptor genes were 
found in mouse dbSNP (Mouse Genomes Project Release Version 5) or were in 
known RNA-editing sites (Danecek et al., 2012). The database of known RNA-editing 
sites was downloaded (ftp://ftp-mouse.sanger.ac.uk/REL-1202-RNAEditing/RNA-
editing.vcf.gz) then converted from mm9 to mm10 coordinates using CrossMap (Zhao 
et al., 2014). I noticed hundreds of mutations that were specific to and shared among 
many of the RNA-seq samples and reasoned they were likely false positives. I filtered 
those mutations using the Fisher’s exact test where the contingency table has the 
number of samples that have three or more variant supporting reads or less than three 
for the rows, and whether the sample is from RNA-seq or WEX for the columns. I 
removed mutations with p-value ≤ 0.01. Finally, I annotated the mutations using 
SnpEff  (Cingolani et al., 2014). 
 I found an average of 30 mutations in the coding exons per mouse tumor, 
ranging from 0 to 104 (Figure 2-14). Compared to mutation rates within coding exons 
in human cancers, our mouse model has a relatively low rate (Figure 2-13). The two 
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most interesting mutations (Kras Q61H and Hras Q61H) overlapped with known 
hotspot mutations in cancer and are known drivers of cancer 
(http://cancerhotspots.org). I otherwise found few recurrent mutations, but found many 
mutations that occurred within protein kinases, many of which are known cancer 
drivers (Figure 2-15).  
 
Figure 2-14: Number and type of mutations in mouse TNBC. 
Shown is the number and breakdown by type of mutation for each mouse tumor. 
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Figure 2-15: Mutations in kinase domains. 
Lolliplot plots of mutations that are within kinase domains. 
 
 
2.3 Mouse precision medicine identifies driver kinases 
 
 Precision medicine assumes that the cancer drivers are at least partially specific 
to each patient’s tumor (Sboner and Elemento, 2016). Hence, the treatment given will 
be tailored to the germline and somatic alterations in each patient. Many research and 
organizational efforts are being made to deliver precision to cancer patients (Letai, 
2017). Chantal et al. developed a pipeline using whole-exome sequencing and a living 
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biobank of patient-derived tumors for drug screens (Pauli et al., 2017). They applied 
their pipeline to 769 cancer patients from across a diverse cancer types and identified 
alterations in known cancer genes in 95.8% of patients. But there were only able to 
identify therapeutic vulnerabilities for 9.6% of patients based on their genetic data. 
They then derived tumor organoids for 56 of the samples and applied high-throughput 
drug dose-response screening on four of them to identify potential therapeutic 
vulnerabilities in the tumor. They were able to identify effect drug combinations for 
all four samples tested. Another precision medicine study is the MOSCATO 01 
prospective clinical trial (Massard et al., 2017). The clinical trial recruited 1,035 
patients with diverse cancer types and acquired a molecular portrait (with one or more 
of RNA-seq, aCGH, WES, and targeted sequencing assays) for 843 of them. They 
were able to identify an actionable molecular target in 49% of tumors (411/843). 
 Here I applied a precision medicine strategy with the sequencing data from our 
TNBC GEM model. I used gene expression, mutations, gene fusions, and CNAs along 
with publicly available databases to identify potential tumor drivers and the likely 
concomitant drugs that could be used to treat the tumor. 
 
2.3.1 Identification of drivers and targetable alterations 
 
I compared the somatic alterations found in our mouse tumors to the OncoKB 
database to identify oncogenic and actionable alterations, and the Cancer Hotspots 
database to identify mouse mutations which overlap with identified hotspots in human 
cancer (M. T. Chang et al., 2016; Chakravarty et al., 2017). I also supplemented data 
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from OncoDB with results from our own findings in the mouse tumors. I also 
identified which somatic alterations overlap genes in the PI3K and MAPK pathways 
(as defined by KEGG) to discern which tumors have alterations that potentially 
activate those pathways. 
To identify overlapping point mutations, I first globally aligned the peptide 
sequences of canonical isoforms of mouse-human homologs using the Needleman-
Wunsch algorithm with the BLOSUM62 matrix (Rice et al., 2000). I then converted 
the amino acid coordinate of the mouse mutation to human coordinates. To identify 
overlapping CNAs, I defined deleted mouse genes as those with copy number 0 and 
amplified genes as those with copy number greater than 3. Finally, I used a z-score 
threshold of +/- 1.5 to identify significant over or under-expressed genes. 
I found oncogenic alterations in 76.7% (56 of 73 tumors) of tumors and 
targetable alterations in 49.3% (36 of 73 tumors) of tumors (Figure 2-16). I also found 
that 75% (54 of 72) of tumors harbored at least one somatic alteration (CNA, 
mutation, or fusion) in any of the mouse protein kinases. Fifteen kinases where 
affected by two or more somatic alterations (Figure 2-17). 
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Figure 2-16: Oncogenic and targetable alterations. 
(A) Shows the proportion of tumors that were identified as having a known oncogenic 
alteration. (B) Shows the proportion of tumors with alterations that can be targeted by 
existing drugs. 
 
 
Figure 2-17: Kinases with two or more alterations. 
Rows are individual kinases that were affected by two or more somatic alterations. 
Columns are the primary tumors. 
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2.3.2 Precision medicine treatment 
 
 Our next step was to take the identified oncogenic alterations and apply 
treatment to a select number of mice. Based on our in vitro validation for the presence 
of the alterations, we chose to target tumors containing Fgfr2 fusions, Raf1 fusion, 
Braf fusion and Met overexpression. For each target, we chose drugs that were (i) have 
high specificity and high competence indicated by low IC50, (ii) have good in vivo 
bioavailability with low in vivo dosing, and (iii) are approved for cancer treatment or 
are currently in phase II or III clinical trial. 
 We treated tumors with either Fgfr2-Dnm3 or Fgfr2-Tns1 gene fusions with 
the FGFR inhibitor, BGJ398. We first validated that the fusion is present using sanger 
sequencing on the cDNA (Figure 2-18). We also demonstrated that the tumors with 
the fusion had higher levels of phospho-FSR2, which is an indicator of FGFR pathway 
activation (Figure 2-19). We treated both Fgfr2 fusions and found that BGJ398 alone 
was sufficient to lead to complete tumor regression (Figure 2-20). We also included a 
couple of negative control treatments. In addition to treatment with no drug, we used 
Met inhibitor, crizotinib, on the Fgfr2-Dnm3 since the tumor has no Met alterations. 
As expected, in all cases the control treatment did not halt tumor growth. Furthermore, 
we applied combination treatments to both Fgfr2 fusions. The tumor with Fgfr2-Dnm3 
has the Brca1 deleted genotype, so is sensitive to the PARP inhibitor, Olaparib. 
Combining Olaparib with BGJ398 lead to complete tumor remission, as was the case 
for BGJ398 alone, but also prevented any tumor relapses for 80 days; whereas 
BGJ398-alone treatment had a 50% recurrence rate (data not shown). For the tumor 
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with Fgfr2-Tns1 fusion, we applied the PI3K inhibitor, BKM120. By itself it slowed 
tumor regression, but when combined with BGJ398 they worked synergistically to 
produce fast and complete tumor remission. 
 We treated the tumor with the Dhx9-Raf1 gene fusion using the MEK 
inhibitor, trametinib (GSK1120212). We validated the presence of the fusion using 
sanger sequencing on the fusion cDNA (Figure 2-18). We also demonstrated that 
tumors with the fusion had higher phospho-ERK levels, which is an indicator of 
MAPK pathway activity (Figure 2-19). We then treated the tumor with trametinib and 
found that it alone significantly delayed tumor growth (Figure 2-20). Moreover, since 
the tumor with the Dhx9-Raf1 fusion was also Brca1 deleted, we treated the tumor 
with olaparib alone or in combination with trametinib. Olaparib alone resulted in 
slowly causing tumor remission, but when combined with trametinib it led to complete 
tumor remission. 
We also treated the tumor with the Dlg1-Braf gene fusion using trametinib. 
After validating the presence of the fusion with sanger sequencing (Figure 2-18), we 
showed that the tumors with the fusion had higher phospho-ERK signaling (Figure 2-
19). Hence, we reasoned that since the tumors had higher MAPK signaling they may 
also be sensitive to MEK inhibition using trametinib. However, treatment with 
trametinib alone only slightly slowed tumor growth (Figure 2-20). Moreover, 
combined trametinib and BKM120 performed slightly better than BKM120 alone, but 
still did not lead to tumor remission. 
 Finally, we treated a tumor overexpressing Met with the Met inhibitor, 
crizotinib. We validated the presence of the fusion by sanger sequencing (Figure 2-18) 
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and showed that tumors with the fusions had higher phospho-ERK (Figure 2-19). 
Treatment of the Met-overexpressed tumor with crizotinib alone only slightly delayed 
tumor growth (Figure 2-20). Similarly, treatment with BKM120 alone also only 
delayed tumor growth. However, combined crizotinib and BKM120 treatment lead to 
tumor regression. 
 
 
Figure 2-18: Sanger sequence validation. 
(A) Fgfr2-Dnm3 fusion. (B) Fgfr2-Tns1 fusion. (C) Dlg1-Braf fusion. (D) Dhx9-Raf1 
fusion. 
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Figure 2-19: Western blots. 
 (A) Western blot showing increased pFRS2 levels in tumors with the Fgfr2-Dnm3 
fusion. (B) Western blot showing increased pERK levels in tumors with the Dhx9-
Raf1 fusion. (C) Western blot showing increased pERK levels in tumors with the Met 
over-expression. (D) Western blot showing increase pERK levels in tumors with the 
Dlg1-Braf fusion. 
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Figure 2-20: Tumor treatment. 
(A) Treatment results on tumors with the Fgfr2-Dnm3 fusion. (B) Treatment results on 
tumors with the Fgfr2-Tns1 fusion. (C) Treatment results on tumors with the Dhx9-
Raf1 fusion. (D) Treatment results on tumors with Met over-expression. (E) Treatment 
results on tumors with the Dlg1-Braf fusion. 
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 In summary, we treated five different somatic alterations involving different 
protein kinases. We were able to validate the presence and signaling consequences for 
all alterations. Most treatments were successful when targeting the kinase alone or in 
combination of another drug. The FGFR inhibitor, BGJ398, was exceptionally 
effective alone in causing tumor remission in Fgfr2-fused tumors. We also found that 
inhibitors targeting Raf1 and Met in Dhx9-Raf1 and Met-overexpressed tumors, 
respectively, were significant in delaying tumor growth. Moreover, when combined 
with other inhibitors they were even more effective than single-target therapy. Finally, 
we applied a MET inhibitor to the tumor harboring the Dlg1-Braf fusion, but only saw 
a slight delay in tumor growth. 
 
2.4 Summary 
 
 In summary, I profiled 72 primary TNBC tumors that were generated from 
Trp53-deficient, with or without Brca1 deficiency, mice. I used a combined RNA-seq 
and WES approach to verify that the GEM model accurately reflects human TNBC, 
identified somatic alterations, and applied treatment using a precision medicine 
approach. Moreover, the analyses revealed a large number of protein kinases that were 
somatically altered, some of which were validated to be driving tumor growth. Our 
results indicate the validity of a precision medicine approach for treating mouse 
TNBC as well as identifying protein kinases that driver tumor growth. 
 The first step in my analysis was to validate that the GEM model reflects 
human TNBC. I verified by IHC and RNA-seq that most tumors lack expression for 
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PR, ER, and HER2, which is what defines human TNBC. Moreover, I used two gene 
expression classifiers to demonstrate that most mouse tumors are of the basal-like 
subtype, which is the breast cancer subtype most often associated with TNBC. Finally, 
I found that the mouse tumors exhibited low mutation rates and high rates of gene 
fusion and CNAs, which are all features of human TNBC. 
 I next sought to characterize the genomic and transcriptomic landscape of the 
mouse tumors. Our first finding revealed a large number of heterogenous gene fusions. 
Few fusions were recurrent across the tumors but there were a number of genes that 
were fused in multiple tumors but involved different gene partners. For example, I 
found Fgfr2 fused to three different gene partners: Tns1, Dnm3, and Zmynd8. I also 
found number of other gene fusions involving protein kinases, including: Dhx9-Raf1, 
Rpl32-Raf1, Dlg1-Braf, Met-Calu, and Met-Itsn1. Next, I surveyed the mutational 
landscape and found low mutation rates and no recurrent mutations. However, I did 
find two mutations that occurred in known hotspot mutations in human cancer: KRAS 
Q61H and HRAS Q61H. I also found a number of nonsynonymous and truncating 
mutations in protein kinases. Finally, I surveyed the CNA landscape and found a very 
heterogenous number of CNAs. I found three recurrent CNAs: Met (a protein kinase), 
Yap1, and Myc. I also found focal CNAs in single tumors affecting known oncogenic 
genes, including: Pten, Egfr, and Fgfr2. 
 I applied a precision medicine approach to the mouse tumors and selected a 
number of somatic alterations for follow-up validation and treatment. I chose the 
following: Fgfr2-Dnm3, Fgfr2-Tns1, Dlg1-Braf, Dhx9-Raf1, and Met over expression. 
Targeted therapy of Fgfr2 fusions using FGFR inhibitors was very successful at 
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causing tumor remission. Targeting Dhx9-Raf1 fusion and Met over expression with 
therapies significantly delayed tumor growth, but when combined with other therapies 
(BKM120 or Olaparib) lead to tumor remission. We attempted to target the Dlg1-Braf 
fusion alone with a MEK inhibitor, but only achieved a minor delay in tumor growth. 
Moreover, combining the MEK inhibitor with BKM120 increased efficacy, but still 
only lead to delay in tumor growth and not tumor remission. 
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CHAPTER 3  
KINOME SUBSTRATE SPECIFICITY 
 
 
 
Understanding which kinases phosphorylate which substrate proteins is of vital 
importance for understanding cellular signaling networks. Kinases use several 
contextual cues that determine which substrates it can phosphorylate, including amino 
acid composition around the phosphorylated serine, threonine, and tyrosine, tissue and 
cellular specificity, and protein interaction networks. 
Over the past few decades, several categories of biochemical and molecular 
technologies have been created to determine the substrates of a given kinase, but each 
has its own set of limitations. Here I outline the general types of technologies, but the 
reader can refer to several good reviews for more in depth discussion (de Oliveira et 
al., 2016; Newman et al., 2014). Some technologies use radio-labeled ATP substrate 
incubated with the kinase and protein substrate of interest to determine reactivity, but 
the main limitation of this approach is that it is low-throughput and many protein 
kinases will phosphorylate almost any protein if incubated long enough, thereby 
resulting in false positives. Protein microarrays print thousands of purified substrate 
proteins to an array and are then incubated with a solution containing ATP and the 
kinase-of-interest. However, since the reaction mixture occurs outside of the 
physiological conditions of the cell, the identified phosphorylation event may not 
really occur in vivo. Additionally, if the phosphorylation event depends on scaffolding 
proteins or other protein interactions, protein microarrays may miss them. The peptide 
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library (discussed later) is another approach with similar limitations to protein 
microarrays. However, one difference is the protein microarray cannot tell where on 
the protein it is being phosphorylated, whereas the peptide library can tell you the 
amino acid context each kinase prefers. Other approaches make use of mass 
spectrometry (MS) for measuring changes in phosphorylation levels of substrates after 
genetic or pharmacological modification of the signaling pathway. In these approaches 
the peptide mixture prior to MS can be phospho-peptide enriched or kinase-specific 
antibodies can be used while the kinase is bound to the substrate. However, since 
kinase signaling networks are complicated and phosphorylation can be transient, the 
identified phosphorylation events cannot always be detected or reliably attributed to 
the kinase-of-interest. 
Computational approaches are an alternative approach for determining kinase 
substrate specificity, with over 50 computational tools that predict kinase substrate 
relations currently published (Bórquez and González-Billault, 2016; de Oliveira et al., 
2016). However, these approaches also have some important limitations. Firstly, the 
vast majority of these tools depend on databases of reported kinase-substrate pairs 
determined from literature and mass-spectrometry experiments, such as 
PhosphoSitePlus and Phospho.ELM (Hornbeck et al., 2004; Dinkel et al., 2011). 
There is the potential that many of the reported kinase-substrate pairs may be false. 
That is, some may not actually occur in vivo or the wrong kinase was attributed as 
being responsible for the site. Secondly, although there are hundreds of thousands of 
reported phosphorylation sites, the vast majority do not have a known kinase assigned 
to them. In addition, there is wide variability in the number of substrates reported for 
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each kinase and most kinases have few or no known substrates. Hence, training a 
classifier for most kinases is not feasible, and for those which training data does exist 
there is a significant class size imbalance problem. 
Computational and molecular approaches for determining kinase-substrate 
pairs both have their limitations, but the peptide library mentioned above provides a 
good compromise. The peptide library determines the kinase’s amino acid preferences 
around the phosphorylated serine, threonine, and tyrosine in the C-terminal and N-
terminal directions (Songyang et al., 1994; 1995). The assay works by mixing the 
purified kinase of interest with a mixture of degenerate peptides and radiolabeled 
ATP. There are 198 degenerate peptide mixtures, where each contains peptides with a 
central, un-phosphorylated serine, threonine, or tyrosine, a fixed amino acid at one of 
the surrounding positions, and the remaining positions contain degenerate amino acids 
(equimolar amounts of each amino acid) (Figure 3-1). After the reaction has 
completed, aliquots of each are transferred to an avidin-coated membrane for imaging. 
Hence, the peptide library does not determine individual kinase-substrate pairs but 
indicates the kinase’s preferences for the surrounding amino acid composition. 
Additional computational methods are necessary to take the kinase’s specificity matrix 
with an appropriate scoring model and other contextual factors to determine which 
substrates the kinase can phosphorylate.  
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Figure 3-1: Kinase peptide library. 
(A) Peptide mixture design for each well for measuring a tyrosine kinase’s amino acid 
selectivity. The yellow character is the fixed amino acid that varies by position on the 
y-axis and amino acid type on the x-axis. The black X’s are degenerate amino acids. 
The red “Y” is the central tyrosine that will be phosphorylated. (B) Example peptide 
library result for human Aurora Kinase B. 
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In this chapter I present peptide library data for several hundred human protein 
kinases and downstream computational analyses. Some parts of this analysis were 
performed in collaboration with Jared Johnson, who generated the peptide library data. 
I start with several analyses that validate the quality of the data and then 
demonstrating how I arrived at a scoring model that uses the peptide library for 
predicting kinase substrates. I then explore phospho-priming, which is a kinase 
signaling mechanism previously unstudied at the global level using computational 
methods. 
 
3.1 Modeling kinase substrate specificity 
 
 The peptide library was performed on 262 kinases. My first task was to assess 
the quality of the data. I performed an unsupervised clustering (t-SNE) on the kinases 
(Figure 3-2 and Figure 3-3) (Maaten and Hinton, 2008), which is a machine learning 
algorithm to visualize high-dimensional data. t-SNE revealed that the kinases separate 
primarily by kinase type, with tyrosine kinases and serine/threonine kinases forming 
separate clusters. I also found through t-SNE that kinases generally group by family 
(Manning et al., 2002). Hence, the kinases cluster based on prior knowledge of kinase 
function and evolutionary history. 
 Next, I explored the relationship between kinase substrate specificity from the 
peptide library with the kinase domain sequences. All protein kinases share an 
evolutionarily conserved ~250 amino acid kinase domain. A phylogenetic tree based 
on the kinase domain has previously been used to reveal the evolutionary relationship 
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among the kinases and family groupings (Manning et al., 2002). However, not every 
amino acid in the kinase domain is important for determining kinase substrate 
specificity. Pau et al. developed a method to identify amino acids in the multiple 
sequence alignment of kinase domains that are more important for determining 
substrate specificity, the so called determinants of specificity (DoS) (Creixell, Palmeri, 
et al., 2015). Furthermore, they found that the correlation between kinase substrate 
specificity and kinase domain sequence increased when restricting the domain to only 
the DoS. I performed a similar analysis using the 68 DoS with KINspect scores ≥ 0.9 
and found a similar increased correlation between kinase domain and kinase 
specificity when restricting to only the DoS. (Figure 3-4). 
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Figure 3-2: t-SNE by kinase type. 
Two-dimensional t-SNE plot showing clear separation of the kinase by type (tyrosine 
kinases and serine/threonine kinases). 
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Figure 3-3: t-SNE by kinase family. 
Two-dimensional t-SNE that shows clear grouping of kinases by kinase family. 
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Figure 3-4: Kinase domain and specificity correlation. 
Kinase domain BLOSUM similarity were computed from the multiple alignment and 
BLOSUM distance scoring approach used by Pau et al. Kinase specificity profile 
similarity was computed using pairwise distance between each peptide library profile 
with spearman correlation. 
 
 
 
My next step was to benchmark the ability of the peptide library data to 
identify each kinase’s known substrates. Several databases exist that curate the 
literature for published kinase-substrate relationships, such as PhosphoSite and 
Phospho.ELM (Hornbeck et al., 2004; Dinkel et al., 2011). Using data from 
PhosphoSite (version MAR_21_2017), I plotted the number of ‘putative’ substrates 
per kinase to demonstrate that most kinases have few or no reported substrates (Figure 
3-5). Moreover, there are 233,567 listed phosphorylation sites, but only 7,141 of them 
assigned to one or more kinase. Therefore, training a classifier for most kinases is not 
possible, and even for those with hundreds of reported substrates still have a large 
class imbalance problem. Hence, making the task of predicting kinase substrates or 
benchmarking an existing algorithm to be challenging. 
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Figure 3-5: Putative kinase substrates. 
Plot of the number of putative kinase substrates per kinase as listed in PhosphoSite. 
 
 
 I next attempted to filter ‘putative’ kinase substrates in PhosphoSite since false 
positive sites would lead the underestimating the performance of the peptide library. 
As explained earlier, some of the sites may be incorrectly reported by either being a 
phosphorylation site that does not actually occur or the wrong kinase was assigned to 
it. For each kinase for which peptide library data was available and had at least 10 
reported substrates in PhosphoSite, I scored each and plotted against three metrics that 
may serve as indicators for the quality of the site. ‘LT_LIT’ is the number of 
publications supporting the phosphorylation site. ‘MS_LIT’ is the number of mass 
spec studies supporting the site. ‘MS_CST’ is the number of mass spec studies 
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performed by Cell Signaling Technology that support the site. I assumed that the 
higher any of the three metrics are the better quality the site. However, plotting 
LT_LIT, MS_LIT, and MS_CST against kinase score yields no obvious relationship 
(Figure 3-6). I also performed similar plots but for each kinase separately and got a 
few kinases with significant correlations, though most were negatively correlated (data 
not shown). Hence, little can be concluded from this analysis. 
 
Figure 3-6: Correlation with quality metrics. 
Plots of (A) LT_LIT, (B) MS_LIT, and (C) MS_CST measures of each 
phosphorylation site against the peptide library score from the kinase that is reported 
to phosphorylate it. 
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 I then benchmarked the kinase specificity profiles from the peptide library to 
identify their reported substrates. I only used kinases that had at least 10 known 
substrates and applied a variety of normalization methods to the raw peptide library 
densitometry data. The scoring algorithm for each individual kinase works by 
computing empirical p-values for each candidate substrate to decide if the kinase can 
phosphorylate it or not. Computing the p-value for a candidate substrate works as 
follows: (1) use the kinase’s normalized peptide library result to score all 
phosphorylation sites in PhosphoSite (tyrosine kinases are restricted to pY sites and 
serine/threonine kinases are restricted to pS/pT), and then (2) use the empirical 
distribution from step (1) to compute the p-value for the candidate substrate. I 
computed several performance metrics for kinase (Figure 3-7). The results show that 
serine/threonine kinases generally perform better than tyrosine kinases and that 
“row_sum” normalization works best. Overall, the peptide library does better than 
random, however, there is room for improvement since many of the published 
algorithms for predicting kinase substrates do significantly better. 
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Figure 3-7: Kinase peptide library performance. 
Metrics for the ability of the kinase peptide library to identify each kinase’s reported 
substrates. The graphs are broken down by kinase type any normalization approach. 
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3.2 Phospho-priming 
 
 Many kinases depend on the presence of surrounding phosphorylated serines, 
threonines, or tyrosines before they can phosphorylate their substrate; a process 
referred to as phospho-priming. Previous research has demonstrated its role in 
phosphorylation signaling. The review by Valk et al. suggests that phospho-priming 
can permit more complex signaling mechanisms than are possible with singly 
phosphorylated sites (Valk et al., 2014). Some examples include: multiple 
phosphorylation sites can create a graduated input (switch-like behavior) and 
sequential phosphorylation sites that each require a different kinase can create an ‘and’ 
gate.  
The peptide library data presented in this thesis measures kinase preference for 
pT and pY and can form the basis for further understanding phospho-priming at a 
global level. As an example, Figure 3-8 shows the pY preferences across the tyrosine 
kinases. Furthermore, to explore the potential prevalence of phospho-priming I 
examined the relative frequencies of different amino acids including pY, pS, and pT 
around reported phosphorylation sites (Figure 3-9). The figures demonstrate that for 
all three types of phosphorylation sites, there is a significant enrichment of other 
phosphorylation sites. Indicating that there is the potential for phospho-priming to 
occur. However, one alternative explanation for the co-occurrence of phosphorylation 
sites is intrinsic instability (He et al., 2009). Portions of many proteins have stretches 
of amino acids that do not form secondary or tertiary structures and are said to be 
intrinsically unstable. Previous research has demonstrated that phosphorylation sites 
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preferentially occur within regions of instability. Hence, the co-occurrence of 
phosphorylation sites could also be due to intrinsic instability. 
  
 
 
 
Figure 3-8: Phospho-tyrosine selectivity. 
Phospho-tyrosine selectivity for each of the tyrosine kinases. Y-axis shows relative 
position to the central phosphorylated tyrosine and y-axis shows the kinase. 
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Figure 3-9: Relative amino acid frequencies. 
(A) Phospho-serine, (B) phospho-threonine, and (C) phospho-tyrosine. 
 
 
3.3 Summary 
 
 Presented in this chapter is the analysis of peptide library profiles of nearly 300 
human protein kinases. I first demonstrated the quality of the data by showing the 
kinase specificity profiles cluster first by kinase type (tyrosine kinases and 
serine/threonine kinases) and then family. I also showed how the correlation between 
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kinase substrate specificity and the amino acid sequence of the kinase domain 
significantly increases when restricting to the DoS instead of full kinase domain. Both 
of these analyses support that the data is of sufficient quality for downstream analyses. 
I then used a simple empirical distribution for each kinase to benchmark the peptide 
library results to identify their reported substrates from PhosphoSite. I found that 
although the kinases certainly do better than a random model, there is room to improve 
the model when compared to other published algorithms that achieve higher accuracy. 
Finally, I explored phospho-priming to a small extent and found that kinases indeed 
have position-specific preferences for pY, pT, and pS. Moreover, using the 
PhosphoSite database, I computed the relative abundance of different amino acids 
(including pT, pY, and pS) around reported phosphorylation sites. I discovered a 
significant enrichment of phosphorylation sites near other phosphorylation sites. 
Hence, these two results indicate the potential significant relevance of phospho-
priming in kinase signaling networks. 
Determining the substrates of a kinase is a challenging problem, and one of the 
limiting factors behind understanding kinome-wide substrate specificity is having 
amino acid preferences on substrates for each kinase. Most kinases have few or no 
reported substrates, so building a model for their amino acid preferences is difficult to 
impossible. However, with the large peptide library dataset presented here that task is 
largely alleviated. But as my results demonstrate, kinase substrate specificity is also 
determined by other contextual cues like tissue/cellular expression and protein 
interaction networks in addition to amino acid content. Hence, further work will have 
to include such data to improve the predictions. 
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CHAPTER 4  
CONCLUDING REMARKS 
 
 In this thesis I have demonstrated the utility of two orthogonal technologies for 
studying kinase function. Using next-generation sequencing, I found a large number of 
somatic alterations that affect protein kinases in the context of a GEM model of 
TNBC. I then focused on a number of those alterations and demonstrated their ability 
to drive tumorigenesis and vulnerability to therapeutic intervention. I then used the 
kinase peptide library from 262 protein kinases to discover their substrate specificity. 
 
4.1 – Kinase drivers in triple-negative breast cancer 
 
I used next-generation sequencing on a large set of primary tumors from a 
GEM model of TNBC. My colleague and I first validated that the GEM model reflects 
human TNBC. We confirmed using RNA-seq and IHC that most of the tumors are 
negative for HER2, PR, and ER, which are the primary markers of human TNBC. I 
also used the RNA-seq data to classify each tumor into one of the five intrinsic 
subtypes using two different algorithms. I found that the vast majority of tumors were 
of the basal subtype, which is the subtype most commonly associated with human 
TNBC. Finally, I demonstrated that the somatic alteration landscape of the tumors 
reflects human TNBC. I showed that the tumors have low mutations rates, but 
heterogenous CNA and gene fusion landscapes. Thus, we demonstrated that the GEM 
model is transcriptionally and genomically similar to human TNBC. 
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I then used a number of bioinformatics algorithms to discover the driver 
mutations, gene fusions, and CNAs. I found few recurrent alterations, except Fgfr2 
fusions and Met, Yap1, and Myc amplifications. A large number of the somatic 
alterations involved protein kinases. I found over a dozen mutations within protein 
kinase domains. Several protein kinases were found involved in in-frame gene fusions, 
including Fgfr2, Braf, Raf1, and Met. I also found CNAs involving protein kinases, 
including focally amplified Met in 10 tumors. In all, as has been shown in human 
breast cancer, protein kinases are a frequent source of tumor drivers. 
 We then selected a number of somatic alterations for follow-up validation, 
functional elucidation, and targeted therapy. We successfully validated for the 
functional relevance of the Fgfr2, Braf, and Raf1 fusions as well as Met, Pten, Egfr, 
and Fgfr2 CNAs. We selected drugs that specifically target each of the above gene 
fusions (including a Met overexpressing tumor) and were able to successfully either 
delay tumor growth or induce tumor regression for most tumors. 
 
4.2 – Kinome substrate specificity 
 
 I used peptide library data for 262 kinases to predict the substrate specificity. I 
validated the quality of the data using unsupervised learning to show the peptide 
library data group the kinases according to kinase type and family. I then 
benchmarked the ability of the peptide library data to predict the kinases’ putative 
substrates. I found that although the peptide library data performs better than random, 
there is room for improvement. Identifying or predicting a kinase’s substrates using 
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either in-vivo, in-vitro, or in-silico methods is challenging. Benchmarking the peptide 
library data relies on a dataset of ‘known’ kinase-substrate pairs, such as from 
PhosphoSite or Phospho.ELM databases. Those databases scan the literature and even 
perform their own experiments (e.g. with mass-spec) for their data. However, it is 
entirely possible that a portion of those reported sites are false. Kinase signaling 
networks are intertwined and phosphorylation events can happen quickly, so in some 
cases a phosphorylation event could be assigned to one kinase while it was actually 
due to a downstream kinase. Furthermore, kinase substrate specificity depends on 
much more than amino acid composition. Cellular localization, tissue specificity, 
protein interaction networks, and more are also important, but were not incorporated 
into the model presented in this thesis. 
 
4.3 – Future work 
 
 The presented analysis on mouse TNBC tumors could be furthered in several 
ways. Only a select few of the identified tumor drivers were chosen for follow-up 
validation and therapeutic targeting (Fgfr2 fusions, Braf fusion, Raf1 fusion, and Met 
over-expression). Many more driver alterations, especially those involving protein 
kinases, were discovered. Validation and targeting more of those alterations could lead 
to new ways of understanding TNBC tumorigenesis and discover new therapeutic 
strategies. TNBC is a very heterogenous disease with few recurrent alterations, so it is 
impractical to identify any drug that can be successful in a large number of tumors. 
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Hence, treatment needs to be tailored to the somatic alterations identified in individual 
tumors. 
 Determining which kinases phosphorylate which substrate is a complex 
problem. The algorithm presented in this work is a basic approach, and so there is 
significant room for improvement. The main route for improvement is the 
incorporation of contextual factors. Although amino acid composition is important for 
kinase specificity, it alone is insufficient for determining which kinase phosphorylates 
which substrate. Cellular localization, tissue specificity, protein interaction networks, 
and more are all important. Phospho-priming is also a ripe area for study using the 
peptide library data, and there are currently no computational analyses have taken a 
global look at phospho-priming (Valk et al., 2014).  
 Finally, there are a few areas of intersection between the two chapters 
presented in this work. Many of the somatic alterations identified in the mouse tumors 
involved protein kinases, including mutations, fusions, and CNAs. These alterations 
likely lead to changes in phosphorylation signaling networks, which can be measured 
using phospho-proteomics. The peptide library data could then be used to identify 
which kinases were responsible for the changing phosphorylation landscape. 
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